CD274 and gastric cancer: This led to the FDA approval of nivolumab in April 2021 for use in advanced GC/GEJC regardless of PD-L1 CPS, though the National Comprehensive Cancer Network (NCCN) guidelines specify their category 1 designation for CPS ≥ 5 [71].